Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 851, Issue -, Pages 43-51Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2019.02.030
Keywords
Triptolide; ESCC; Proliferation; Metastasis; MAPK/ERK pathway
Categories
Funding
- Startup Foundation for Doctors of Shanxi Medical University [BS03201645]
- Scientific Research Foundation of the Shanxi Province for Returned Scholars [2017-065]
- National Natural Science Foundation of China [81802440]
Ask authors/readers for more resources
Triptolide, the component of traditional Chinese herb, has been used as an inflammatory medicine and reported to be anti-tumor for various cancers recently. However, the effect of triptolide on Esophageal Squamous Cell Cancer (ESCC) has not yet been elucidated. In the study, we found that triptolide significantly inhibited cell proliferation, invasion, migration and survivability of ESCC cells. Moreover, we observed that triptolide induced ESCC cell cycle arrest at the G1/S phase and apoptosis through cyclin D1-CDK4/6 regulation and caspases activation. In addition, we revealed that triptolide regulates cell apoptosis and metastasis by p53 and mitogen-activated protein kinases/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway, respectively. Meanwhile, the inhibitory effect of triptolide on ESCC was validated in mouse xenograft model. So, we propose that triptolide may be a candidate drug for ESCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available